GDUFA Success Depends On Industry Changes As Much As Review Improvements, FDA Says
“This is a shared responsibility. We have to have a shared sense of urgency,” Acting OGD director tells GPhA.
You may also be interested in...
Refuse-to-receive rates for ANDAs are down, suggesting sponsors better understand the standards for quality applications, Office of Generic Drugs Director Sally Choe says in first speech to industry.
Incoming Office of Generic Drugs Director Sally Choe is largely unfamiliar to industry, but potentially offers a new perspective.
US FDA's expedited pathway for generics seems to provide more benefits for amendments than for original ANDAs.